186 related articles for article (PubMed ID: 36749875)
1. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
Lozano-Rabella M; Garcia-Garijo A; Palomero J; Yuste-Estevanez A; Erhard F; Farriol-Duran R; Martín-Liberal J; Ochoa-de-Olza M; Matos I; Gartner JJ; Ghosh M; Canals F; Vidal A; Piulats JM; Matías-Guiu X; Brana I; Muñoz-Couselo E; Garralda E; Schlosser A; Gros A
Clin Cancer Res; 2023 Jun; 29(12):2250-2265. PubMed ID: 36749875
[TBL] [Abstract][Full Text] [Related]
2. Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies.
Fox BA; Urba WJ; Jensen SM; Page DB; Curti BD; Sanborn RE; Leidner RS
Clin Cancer Res; 2023 Jun; 29(12):2173-2175. PubMed ID: 37040070
[TBL] [Abstract][Full Text] [Related]
3. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
Elife; 2020 Apr; 9():. PubMed ID: 32314731
[TBL] [Abstract][Full Text] [Related]
4. Proteogenomic discovery of cancer antigens: Neoantigens and beyond.
Kanaseki T; Tokita S; Torigoe T
Pathol Int; 2019 Sep; 69(9):511-518. PubMed ID: 31397525
[TBL] [Abstract][Full Text] [Related]
5. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
6. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
7. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
8. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
[TBL] [Abstract][Full Text] [Related]
10. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
[No Abstract] [Full Text] [Related]
11. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
12. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
13. Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens.
Malekzadeh P; Yossef R; Cafri G; Paria BC; Lowery FJ; Jafferji M; Good ML; Sachs A; Copeland AR; Kim SP; Kivitz S; Parkhurst MR; Robbins PF; Ray S; Xi L; Raffeld M; Yu Z; Restifo NP; Somerville RPT; Rosenberg SA; Deniger DC
Clin Cancer Res; 2020 Mar; 26(6):1267-1276. PubMed ID: 31996390
[TBL] [Abstract][Full Text] [Related]
14. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
[TBL] [Abstract][Full Text] [Related]
15. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
16. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
17. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
18. Proteogenomics: advances in cancer antigen research.
Kanaseki T; Torigoe T
Immunol Med; 2019 Jun; 42(2):65-70. PubMed ID: 31318319
[TBL] [Abstract][Full Text] [Related]
19. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
Peri A; Greenstein E; Alon M; Pai JA; Dingjan T; Reich-Zeliger S; Barnea E; Barbolin C; Levy R; Arnedo-Pac C; Kalaora S; Dassa B; Feldmesser E; Shang P; Greenberg P; Levin Y; Benedek G; Levesque MP; Adams DJ; Lotem M; Wilmott JS; Scolyer RA; Jönsson GB; Admon A; Rosenberg SA; Cohen CJ; Niv MY; Lopez-Bigas N; Satpathy AT; Friedman N; Samuels Y
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651586
[TBL] [Abstract][Full Text] [Related]
20. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
